COVID-19 severity in patients with chronic lymphocytic leukemia treated with venetoclax: a single-center observational cohort study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
COVID-19 severity in patients with chronic lymphocytic leukemia treated with venetoclax: a single-center observational cohort study ; day:18 ; month:4 ; year:2024 ; pages:1-8
Annals of hematology ; (18.4.2024), 1-8
- Urheber
-
Thau, Sophie
Poulsen, Christian Bjørn
Brieghel, Christian
Larsen, Morten Kranker
Wiese, Lothar
Nielsen, Xiaohui Chen
Pedersen, Lars Møller
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s00277-024-05738-4
- URN
-
urn:nbn:de:101:1-2406302120145.709737985433
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:00 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Thau, Sophie
- Poulsen, Christian Bjørn
- Brieghel, Christian
- Larsen, Morten Kranker
- Wiese, Lothar
- Nielsen, Xiaohui Chen
- Pedersen, Lars Møller
- SpringerLink (Online service)
Ähnliche Objekte (12)
Measurable residual disease in Japanese patients with relapsed or refractory chronic lymphocytic leukemia treated with venetoclax
Venetoclax treatment for chronic lymphocytic leukemia/small lymphocytic leukemia in Japan: post-marketing surveillance
Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia
Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia
Cost-effectiveness and budget impact of venetoclax in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia in Switzerland
Real-world experience with venetoclax-based therapy for patients with myeloid sarcoma
COVID-19 among fit patients with CLL treated with venetoclax-based combinations
Cardiotoxicity of venetoclax in patients with acute myeloid leukemia: comparison with anthracyclines
Venetoclax for Treating Chronic Lymphocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Venetoclax: A Novel Therapeutic Agent for CLL with CNS Involvement
Budget Impact of 12-Month Fixed Treatment Duration Venetoclax in Combination with Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia Patients in the United States
Low incidence of tumor lysis syndrome in elderly patients with chronic lymphocytic leukemia treated with venetoclax under real-world conditions: results from the prospective observational VeRVe study
Measurable residual disease in Japanese patients with relapsed or refractory chronic lymphocytic leukemia treated with venetoclax
Venetoclax treatment for chronic lymphocytic leukemia/small lymphocytic leukemia in Japan: post-marketing surveillance
Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia
Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia
Cost-effectiveness and budget impact of venetoclax in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia in Switzerland
Real-world experience with venetoclax-based therapy for patients with myeloid sarcoma
COVID-19 among fit patients with CLL treated with venetoclax-based combinations
Cardiotoxicity of venetoclax in patients with acute myeloid leukemia: comparison with anthracyclines
Venetoclax for Treating Chronic Lymphocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Venetoclax: A Novel Therapeutic Agent for CLL with CNS Involvement
Budget Impact of 12-Month Fixed Treatment Duration Venetoclax in Combination with Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia Patients in the United States
Low incidence of tumor lysis syndrome in elderly patients with chronic lymphocytic leukemia treated with venetoclax under real-world conditions: results from the prospective observational VeRVe study
Measurable residual disease in Japanese patients with relapsed or refractory chronic lymphocytic leukemia treated with venetoclax
Venetoclax treatment for chronic lymphocytic leukemia/small lymphocytic leukemia in Japan: post-marketing surveillance
Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia
Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia
Cost-effectiveness and budget impact of venetoclax in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia in Switzerland
Real-world experience with venetoclax-based therapy for patients with myeloid sarcoma
COVID-19 among fit patients with CLL treated with venetoclax-based combinations
Cardiotoxicity of venetoclax in patients with acute myeloid leukemia: comparison with anthracyclines
Venetoclax for Treating Chronic Lymphocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Venetoclax: A Novel Therapeutic Agent for CLL with CNS Involvement
Budget Impact of 12-Month Fixed Treatment Duration Venetoclax in Combination with Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia Patients in the United States